Abstract
During the developmental period of the adenovirus vaccine, field trials of bivalent Types 4 and 7 vaccine conducted by the Army Medical Service in 1956 and 1957 resulted in 90% to 98% reduction in hospitalization due to adenovirus disease in recruits. During the respiratory disease season of 1960-1961, a standardized, commercially prepared, Types 4 and 7 vaccine was used at all recruit training stations. Preliminary results indicate that this vaccine was about 50% effective in reducing hospitalization resulting from adenovirus disease. It is evident from the earlier experience that, even though the commercial vaccine now being used is estimated to have saved the Army about $5,000,000 during the last respiratory disease season, there is an urgent requirement to make available adenovirus vaccine of greater antigenicity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
